Table 2.
Relationship between immune cell subset infiltration and clinicopathologic features of pure ductal carcinoma in situ
| Clinicopathologic characteristics | CD4+ TIL | CD8+ TIL | FOXP3+ TIL | PD-L1+ IC | ||||
|---|---|---|---|---|---|---|---|---|
| No. of TILs | p value | No. of TILs | p value | No. of TILs | p value | Frequency (%) | p value | |
| Age (year) | 0.577 | 0.218 | 0.815 | 0.792 | ||||
| < 50 | 19.7 (4.2–50.7) | 12.7 (6.2–26.7) | 0.0 (0.0–1.0) | 21/132 (15.9) | ||||
| ≥ 50 | 19.0 (3.8–44.5) | 12.0 (4.2–22.2) | 0.0 (0.0–1.0) | 13/89 (14.6) | ||||
| DCIS extent (cm) | 0.950 | 0.799 | 0.811 | 0.929 | ||||
| < 2.5 | 19.7 (5.0–47.5) | 12.7 (5.3–24.2) | 0.0 (0.0–1.0) | 21/138 (15.2) | ||||
| ≥ 2.5 | 17.3 (3.7–49.7) | 11.3 (5.0–26.2) | 0.0 (0.0–1.0) | 13/83 (15.7) | ||||
| Nuclear grade | < 0.001 | 0.001 | < 0.001 | < 0.001 | ||||
| Low to intermediate | 12.7 (2.0–37.5) | 10.0 (4.7–18.2) | 0.0 (0.0–0.0) | 11/142 (7.7) | ||||
| High | 25.3 (11.5–77.8) | 15.7 (8.0–35.8) | 0.0 (0.0–3.0) | 23/79 (29.1) | ||||
| Comedo-type necrosis | 0.004 | 0.002 | 0.008 | < 0.001 | ||||
| Absent | 16.0 (3.4–42.0) | 10.7 (5.3–20.1) | 0.0 (0.0–0.0) | 17/174 (9.8) | ||||
| Present | 31.5 (13.6–86.1) | 22.5 (8.5–41.5) | 0.0 (0.0–5.0) | 17/47 (36.2) | ||||
| ER | 0.026 | 0.025 | 0.004 | 0.043 | ||||
| Negative | 34.0 (13.6–82.4) | 22.5 (7.6–48.8) | 0.5 (0.0–5.0) | 8/27 (29.6) | ||||
| Positive | 17.0 (3.7–43.5) | 11.8 (5.3–22.0) | 0.0 (0.0–0.0) | 26/194 (13.4) | ||||
| PR | 0.027 | < 0.001 | 0.002 | 0.019 | ||||
| Negative | 34.0 (12.1–76.3) | 24.2 (10.2–48.9) | 0.0 (0.0–4.9) | 11/40 (27.5) | ||||
| Positive | 16.0 (3.7–42.0) | 10.7 (4.7–19.5) | 0.0 (0.0–0.0) | 23/181 (12.7) | ||||
| HER2 | 0.354 | 0.010 | 0.004 | 0.059 | ||||
| Negative | 17.3 (3.8–44.5) | 12.0 (5.2–22.0) | 0.0 (0.0–0.0) | 25/189 (13.2) | ||||
| Positive | 28.7 (6.8–73.2) | 22.0 (7.3–48.5) | 0.0 (0.0–5.2) | 9/32 (28.1) | ||||
| Ki-67 index | 0.001 | 0.009 | < 0.001 | < 0.001 | ||||
| < 10% | 15.8 (3.4–40.1) | 11.0 (4.9–20.2) | 0.0 (0.0–0.0) | 17/164 (10.4) | ||||
| ≥ 10% | 34.8 (9.3–96.2) | 16.2 (8.3–36.3) | 0.0 (0.0–5.0) | 17/57 (29.8) | ||||
| P53 | 0.001 | 0.041 | 0.016 | 0.092 | ||||
| Negative | 16.3 (3.7–40.4) | 11.5 (4.9–22.4) | 0.0 (0.0–0.1) | 26/192 (13.5) | ||||
| Positive | 49.0 (18.8–80.8) | 17.0 (9.4–31.2) | 0.0 (0.0–3.0) | 8/29 (27.6) | ||||
For CD4+, CD8+, and FOXP3+ TILs, p values were calculated by the Mann-Whitney U test, and data are presented as median (interquartile range)
For PD-L1+ IC, p values were calculated by chi-square or Fisher’s exact test, and data are presented as frequency (%)
TIL tumor-infiltrating lymphocyte, IC immune cell, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2